tailieunhanh - Báo cáo y học: " Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: " Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension. | Respiratory Research BioMed Central Research Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension Annette S Droste1 David Rohde1 Mirko Voelkers1 Arthur Filusch1 Thomas Bruckner2 Mathias M Borst1 Hugo A Katus1 and F Joachim Meyer 1 Open Access Address Department of Cardiology Angiology and Respiratory Medicine Heidelberg Germany and institute for Medical Biometry and Informatics of the University Heidelberg Germany Email Annette S Droste - David Rohde - Mirko Voelkers - Arthur Filusch - Thomas Bruckner - Mathias M Borst - Hugo A Katus - F Joachim Meyer - Corresponding author Published 30 December 2009 Respiratory Research 2009 10 129 doi l465-992l-l0-l29 Received 10 September 2009 Accepted 30 December 2009 This article is available from http content l0 l 129 2009 Droste et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background In idiopathic pulmonary arterial hypertension IPAH peripheral airway obstruction is frequent. This is partially attributed to the mediator dysbalance particularly an excess of endothelin-l ET-1 to increased pulmonary vascular and airway tonus and to local inflammation. Bosentan ET-l receptor antagonist improves pulmonary hemodynamics exercise limitation and disease severity in IPAH. We hypothesized that bosentan might affect airway obstruction. Methods In 32 IPAH-patients 19 female WHO